← Leaderboards
Jeffery L Meier
Iowa City Va Medical Center
$758,264
Attributed
$931,514
Total exposure
24
Grants
15
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $189K · FY2005–25$200K$150K$100K$50K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$931,514 · 22
VA$0 · 2
By mechanism
M01$379,214 · 20
R21$346,500 · 1
R29$205,800 · 1
I01$0 · 2
Top collaborators
- David H. Price2 shared
Others in their field
Top investigators on “Cytomegalovirus”
- Constance Ann Benson · University Of California, San Diego$154,530,762
- Curtis L Meinert · Johns Hopkins University$72,267,482
- Louis J. Picker · Oregon Health And Science University$67,787,971
- Robert Turner Schooley · University Of Colorado Denver$42,307,156
- Dan H. Barouch · Fred Hutchinson Cancer Center$34,316,808
- Jay A Nelson · Oregon Health & Science University$28,085,685
Research focus
CytomegalovirusInfectionGene ExpressionCytomegalovirus InfectionsViralTranscription FactorVirusVeteransBaseCell TypeCell ModelAntiviral AgentsDesignMortality RiskPriceGenetic TranscriptionCongenital AbnormalityLinkProgramsEnhancersImpairmentElementsDna Polymerase IiImmune System
Grant awards (40)
Mechanisms Regulating Cytomegalovirus$0
I01 · FY2025 · VA · contact PI
Mechanisms Regulating Cytomegalovirus$0
I01 · FY2024 · VA · contact PI
Mechanisms Regulating Cytomegalovirus$0
I01 · FY2023 · VA · contact PI
Mechanisms regulating cytomegalovirus$0
I01 · FY2022 · VA · contact PI
Mechanisms regulating cytomegalovirus$0
I01 · FY2021 · VA · contact PI
Mechanisms regulating cytomegalovirus$0
I01 · FY2020 · VA · contact PI
Transcriptional Mechanisms Controlling HCMV Infection$157,500
R21 · FY2019 · AI · contact PI
Mechanisms regulating cytomegalovirus$0
I01 · FY2019 · VA · contact PI
Transcriptional Mechanisms Controlling HCMV Infection$189,000
R21 · FY2018 · AI · contact PI
Control of Human Cytomegalovirus$0
I01 · FY2015 · VA · contact PI
Control of Human Cytomegalovirus$0
I01 · FY2014 · VA · contact PI
Control of Human Cytomegalovirus$0
I01 · FY2013 · VA · contact PI
Control of Human Cytomegalovirus$0
I01 · FY2012 · VA · contact PI
ACTG A5001 - AIDS LONGITUDINAL LINKED RANDOMIZED TRIALS$10,012
M01 · FY2007 · RR · contact PI
ACTG A5202 & ACTG A5224S EMTRICITABINE/TENOFOVIR OR ABACAVIR/LAMIVUDINE FOR HIV$4,805
M01 · FY2007 · RR · contact PI
ACTG A5211 HIV-1 ENTRY INHIBITOR, SCH 417690, TO TREAT HIV INFECTED SUBJECTS$1,201
M01 · FY2007 · RR · contact PI
ACTG A5201 ATAZANAVIR/RITONAVIR AFTER SUSTAINED VIROLOGIC SUPPRESSION$800
M01 · FY2007 · RR · contact PI
ACTG A5211 HIV-1 ENTRY INHIBITOR, SCH 417690, TO TREAT HIV INFECTED SUBJECTS$24,175
M01 · FY2006 · RR · contact PI
ACTG A5001 - AIDS LONGITUDINAL LINKED RANDOMIZED TRIALS$22,617
M01 · FY2006 · RR · contact PI
ACTG A5202 & ACTG A5224S EMTRICITABINE/TENOFOVIR OR ABACAVIR/LAMIVUDINE FOR HIV$15,598
M01 · FY2006 · RR · contact PI
ACTG A5142 - PHASE III DRUG THERAPY FOR HIV-1 INFECTION$13,258
M01 · FY2006 · RR · contact PI
ACTG A5201 ATAZANAVIR/RITONAVIR AFTER SUSTAINED VIROLOGIC SUPPRESSION$12,477
M01 · FY2006 · RR · contact PI
ACTG A5030 VALGANCICLOVIR PRE-EMPTIVE THERAPY FOR CMV$5,458
M01 · FY2006 · RR · contact PI
ACTG A5186 FISH OIL AND FENOFIBRATE IN SUBJECTS ON HAART$4,679
M01 · FY2006 · RR · contact PI
ACTG A5095 THREE PROTEASE INHIBITOR-SPARING REGIMENS IN HIV PATIENTS$1,326
M01 · FY2006 · RR · contact PI
ACTG A5095 THREE PROTEASE INHIBITOR-SPARING REGIMENS IN HIV PATIENTS$50,511
M01 · FY2005 · RR
ACTG A5001 - AIDS LONGITUDINAL LINKED RANDOMIZED TRIALS$22,889
M01 · FY2005 · RR
ACTG A5142 - PHASE III DRUG THERAPY FOR HIV-1 INFECTION$22,889
M01 · FY2005 · RR
ACTG A5186 FISH OIL AND FENOFIBRATE IN SUBJECTS ON HAART$18,942
M01 · FY2005 · RR
ACTG A5030 VALGANCICLOVIR PRE-EMPTIVE THERAPY FOR CMV$10,259
M01 · FY2005 · RR
ACTG A5211 HIV-1 ENTRY INHIBITOR, SCH 417690, TO TREAT HIV INFECTED SUBJECTS$7,892
M01 · FY2005 · RR
ACTG A5174/A5198S IMPROVING IMMUNE RECONSTITUTION WITH GROWTH HORMONE IN HIV$6,315
M01 · FY2005 · RR
INFORMED CONSENT TO USE STORED HUMAN BIOLOGICAL MATERIALS$3,156
M01 · FY2005 · RR
ACTG A5095 Three Protease Inhibitor-Sparing Regimens$59,255
M01 · FY2004 · RR
ACTG A5001 - AIDS Longitudinal Linked Randomized Trials$31,796
M01 · FY2004 · RR
ACTG A5142 - PHASE III DRUG THERAPY FOR HIV-1 INFECTION$15,175
M01 · FY2004 · RR
ACTG A5174/A5198S IMPROVING IMMUNE RECONSTITUTION$10,839
M01 · FY2004 · RR
ACTG A5030 VALGANCICLOVIR PRE-EMPTIVE THERAPY FOR CMV$2,890
M01 · FY2004 · RR
REGULATION OF CYTOMEGALOVIRUS INFECTION OF MONOCYTES$102,900
R29 · FY2001 · AI
REGULATION OF CYTOMEGALOVIRUS INFECTION OF MONOCYTES$102,900
R29 · FY2000 · AI